



DE-ESCALATE



Who we are

DE-ESCALATE unites clinicians, researchers, health economists and patient representatives to improve care for people with metastatic hormone-sensitive prostate cancer.

What we are working on

A 1,600-patient trial tests whether planned treatment breaks can maintain survival while reducing toxicity, treatment burden, costs and improving quality of life.

What's the one thing we need next

We need clinicians and centres to recruit eligible patients, generating robust evidence on whether intermittent treatment can safely replace continuous therapy.



**5 years Mission Cancer:
Stronger Through Connection**

BRUSSELS

29 SEPTEMBER – 01 OCTOBER



For more info visit:
www.deescalate-horizon.eu



EUROPEAN UNION

DE-ESCALATE

